0001662244falseDecember 20, 202300016622442023-10-032023-10-0300016622442023-12-202023-12-20







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2023



Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






99 Hayden Street, Building B, Suite 450


Lexington, Massachusetts



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s Telephone Number, Including Area Code: 857 285-4140


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class




Name of each exchange on which registered

Common Stock, $0.001 par value per share




The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 22, 2023, the Compensation Committee of the Board of Directors of Cyteir Therapeutics, Inc. (the "Company") approved a retention program under which the Company’s Chief Executive Officer, Dr. Markus Renschler, and the Company’s Chief Financial Officer, David Gaiero, will be entitled to a retention bonus in 2024 similar to the one approved on January 17, 2023 for 2023, and reported on Form 8-K/A on February 3, 2023. The retention bonus will be an amount equal to 150% of the executive officer’s target annual bonus, prorated for the period employed during the year.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.










December 22, 2023


/s/ David Gaiero




Name: David Gaiero
Title: Chief Financial Officer and Treasurer


Document and Entity Information
Dec. 20, 2023
Oct. 03, 2023
Cover [Abstract]    
Amendment Flag   false
Entity Central Index Key   0001662244
Document Type   8-K
Document Period End Date Dec. 20, 2023  
Entity Registrant Name   Cyteir Therapeutics, Inc.
Entity Incorporation State Country Code   DE
Securities Act File Number   001-40499
Entity Tax Identification Number   45-5429901
Entity Address, Address Line One   99 Hayden Street, Building B
Entity Address, Address Line Two   Suite 450
Entity Address, City or Town   Lexington
Entity Address, State or Province   MA
Entity Address, Postal Zip Code   02421
City Area Code   857
Local Phone Number   285-4140
Written Communications   false
Soliciting Material   false
Pre Commencement Tender Offer   false
Pre Commencement Issuer Tender Offer   false
Security 12b Title   Common Stock, $0.001 par value per share
Trading Symbol   CYT
Security Exchange Name   NASDAQ
Entity Emerging Growth Company   true
Entity Ex Transition Period   false

Cyteir Therapeutics (NASDAQ:CYT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Cyteir Therapeutics Charts.
Cyteir Therapeutics (NASDAQ:CYT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Cyteir Therapeutics Charts.